LTR Pharma Limited (ASX:LTP)

LTR Pharma Statistics

Total Valuation

LTR Pharma has a market cap or net worth of AUD 97.22 million. The enterprise value is 65.42 million.

Market Cap	97.22M
Enterprise Value	65.42M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

LTR Pharma has 181.73 million shares outstanding. The number of shares has increased by 19.96% in one year.

Current Share Class	181.73M
Shares Outstanding	181.73M
Shares Change (YoY)	+19.96%
Shares Change (QoQ)	+18.36%
Owned by Insiders (%)	5.41%
Owned by Institutions (%)	0.70%
Float	106.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	64.46
PB Ratio	3.09
P/TBV Ratio	3.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-11.69
EV / Sales	43.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.70

Financial Position

The company has a current ratio of 45.78

Current Ratio	45.78
Quick Ratio	45.76
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-265,518.52

Financial Efficiency

Return on equity (ROE) is -32.47% and return on invested capital (ROIC) is -22.16%.

Return on Equity (ROE)	-32.47%
Return on Assets (ROA)	-21.45%
Return on Invested Capital (ROIC)	-22.16%
Return on Capital Employed (ROCE)	-19.38%
Weighted Average Cost of Capital (WACC)	36.57%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.08
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -26.88% in the last 52 weeks. The beta is 5.88, so LTR Pharma's price volatility has been higher than the market average.

Beta (5Y)	5.88
52-Week Price Change	-26.88%
50-Day Moving Average	0.54
200-Day Moving Average	0.46
Relative Strength Index (RSI)	41.43
Average Volume (20 Days)	322,380

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, LTR Pharma had revenue of AUD 1.51 million and -5.59 million in losses. Loss per share was -0.03.

Revenue	1.51M
Gross Profit	-1.28M
Operating Income	-6.11M
Pretax Income	-5.59M
Net Income	-5.59M
EBITDA	-6.10M
EBIT	-6.11M
Loss Per Share	-0.03

Balance Sheet

The company has 31.81 million in cash and n/a in debt, with a net cash position of 31.81 million or 0.18 per share.

Cash & Cash Equivalents	31.81M
Total Debt	n/a
Net Cash	31.81M
Net Cash Per Share	0.18
Equity (Book Value)	31.51M
Book Value Per Share	0.17
Working Capital	31.37M

Cash Flow

In the last 12 months, operating cash flow was -4.44 million and capital expenditures -13,168, giving a free cash flow of -4.45 million.

Operating Cash Flow	-4.44M
Capital Expenditures	-13,168
Free Cash Flow	-4.45M
FCF Per Share	-0.02

Margins

Gross Margin	-84.75%
Operating Margin	-404.86%
Pretax Margin	-370.83%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LTR Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.96%
Shareholder Yield	-19.96%
Earnings Yield	-5.75%
FCF Yield	-4.58%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LTR Pharma has an Altman Z-Score of 123.81 and a Piotroski F-Score of 2.

Altman Z-Score	123.81
Piotroski F-Score	2